Case number 1:20-cv-00019
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mylan Pharmaceuticals Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 26, 2025 | 360 | NOTICE of Appearance by Garrett Matthew Spiker on behalf of All Defendants (Spiker, Garrett) (Entered: 06/26/2025) (2) |
| Jun 25, 2025 | 358 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Reply Report of William Curtis Biggs, MD re: Secondary Considerations Relating to U.S. Patent No. 11,911,388). (O'Brien, William) (Entered: 06/25/2025) (2) |
| Jun 25, 2025 | 359 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 6.25.25). (O'Brien, William) (Entered: 06/25/2025) (2) |
| Jun 23, 2025 | 357 | ORDER granting 355 Motion of Jillian M. Schurr for Leave to Appear Pro Hac Vice on behalf of Mylan Inc., Mylan Laboratories Limited, and Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 6/23/2025. (dk) (Entered: 06/23/2025) (1) |
| Jun 18, 2025 | 355 | MOTION for Leave to Appear Pro Hac Vice (Jillian M. Schurr) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 06/18/2025) (0) |
| Jun 18, 2025 | 356 | Pro Hac Vice filing fee for Jillian Schurr in the amount of $200.00 paid. Receipt Number: 200021199. (jb) (Entered: 06/18/2025) (0) |
| Jun 17, 2025 | 352 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 6/17/2025. (jb) (Copy to counsel of record) (Entered: 06/17/2025) (0) |
| Jun 11, 2025 | 348 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Rebuttal Report of William Curtis Biggs regarding Noninfringement of U.S. Patent No. 11,911,388, the Responsive Report of S. Craig Dyar Ph. D. Supporting Non-Infringement of U.S. Patent No. 11,033,552 with Exhibits, and documents bearing bates numbers MYLAN_LINA_00032617 through MYLAN_LINA_000032625. (Copland, Gordon) (Entered: 06/11/2025) (2) |
| Jun 11, 2025 | 349 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Rebuttal Expert Report of M. Amiji, Ph.D., R.Ph. Regarding Invalidity of U.S. Patent No. 11,033,552; Rebuttal Expert Report of Mitchell H. Rosner, MD; and documents bearing bates numbers BILINA00354095 through BILINA00355505. (Pogue, David) (Entered: 06/11/2025) (1) |
| May 28, 2025 | 347 | JOINT STIPULATION AND ORDER TO MODIFY SCHEDULE. Signed by Chief District Judge Thomas S. Kleeh on 05/28/2025. (snc) (Entered: 05/28/2025) (3) |
| May 23, 2025 | 346 | JOINT STIPULATION AND [PROPOSED] ORDER TO MODIFY SCHEDULE Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Pogue, David) (Entered: 05/23/2025) (3) |
| May 22, 2025 | 345 | ORDER RESCHEDULING PRETRIAL CONFERENCE BY ZOOM. The pretrial conference in this matter is RESCHEDULED for August 4, 2025, at 1:30 p.m., by Zoom videoconference. Signed by Chief District Judge Thomas S. Kleeh on 05/22/2025. (snc) (Entered: 05/22/2025) (2) |
| May 12, 2025 | 342 | ***SEALED***ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL (ECF NOS. 339 , 341 ). Signed by Chief District Judge Thomas S. Kleeh on 05/12/2025. (Copy to counsel) (snc) (Entered: 05/12/2025) (0) |
| May 9, 2025 | 340 | Other Document PLAINTIFFS' OPENING CLAIM CONSTRUCTION BRIEF filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21)(Pogue, David) (Entered: 05/09/2025) (0) |
| May 8, 2025 | 336 | ORDER granting 328 Motion for Leave to Appear Pro Hac Vice (Shaoyao Yu). Signed by Chief District Judge Thomas S. Kleeh on 05/08/2025. (snc) (Entered: 05/08/2025) (1) |
| May 8, 2025 | 337 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Mylan Defendants' Final Invalidity Contentions). (O'Brien, William) (Entered: 05/08/2025) (1) |
| May 8, 2025 | 338 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs' Final Infringement Contentions. (Pogue, David) (Entered: 05/08/2025) (1) |
| May 7, 2025 | 332 | ORDER. The trial in this matter is RESCHEDULED for August 25, 2025, at 9:30 a.m., at the Wheeling, West Virginia, point of holding court (North Courtroom). This is a change in location only. Signed by Chief District Judge Thomas S. Kleeh on 05/07/2025. (snc) (Entered: 05/07/2025) (1) |
| May 7, 2025 | 333 | Pro Hac Vice Filing fee: $ 200, receipt number 100004036. (for S. Yu) (snc) (Entered: 05/07/2025) (0) |
| May 7, 2025 | 334 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 4.22.25). (O'Brien, William) (Entered: 05/07/2025) (1) |
| May 7, 2025 | 335 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 5.2.25). (O'Brien, William) (Entered: 05/07/2025) (1) |
| May 2, 2025 | 331 | JOINT STIPULATION AND ORDER TO MODIFY SCHEDULE. Signed by Chief District Judge Thomas S. Kleeh on 05/02/2025. (snc) (Entered: 05/02/2025) (3) |
| Apr 28, 2025 | 329 | JOINT STIPULATION AND [PROPOSED] ORDER TO MODIFY SCHEDULE ( Other Document ) filed by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 04/28/2025) (3) |
| Apr 28, 2025 | 330 | JOINT STIPULATION AND ORDER REGARDING ADMISSIBILITY OF DOCUMENTS. Signed by Chief District Judge Thomas S. Kleeh on 04/28/2025. (snc) (Entered: 04/28/2025) (5) |
| Apr 25, 2025 | 328 | MOTION for Leave to Appear Pro Hac Vice of Shaoyao Yu by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment A, # 2 Exhibit A-WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 04/25/2025) (0) |
| Apr 24, 2025 | 326 | STIPULATION AND [PROPOSED] ORDER REGARDING ADMISSIBILITY OF DOCUMENTS by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG. (Pogue, David) (Entered: 04/24/2025) (5) |
| Apr 24, 2025 | 327 | MOTION for Leave to Appear Pro Hac Vice of Shaoyao Yu by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order, # 2 Exhibit A, # 3 Attachment WVSB Receipt)(Ruby, Steven) (Entered: 04/24/2025) (0) |
| Apr 22, 2025 | 325 | STIPULATION AND ORDER TO EXTEND DEADLINE. The deadline for the parties to Stipulate to Admissibility of Business Records for Trial be extended to April 24, 2025. Signed by Chief District Judge Thomas S. Kleeh on 04/22/2025. (snc) (Entered: 04/22/2025) (2) |
| Apr 21, 2025 | 323 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Documents produced on 4.11.25). (O'Brien, William) (Entered: 04/21/2025) (1) |
| Apr 21, 2025 | 324 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Proposed Constructions and Supporting Intrinsic Evidence). (O'Brien, William) (Entered: 04/21/2025) (1) |
| Apr 17, 2025 | 320 | STIPULATION AND ORDER TO EXTEND DEADLINE. Signed by Chief District Judge Thomas S Kleeh on 4/17/2025. (dk) (Entered: 04/17/2025) (2) |
| Apr 17, 2025 | 321 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Proposed Claim Constructions and Identification of Intrinsic Evidence. (Pogue, David) (Entered: 04/17/2025) (1) |
| Apr 17, 2025 | 322 | STIPULATION AND [PROPOSED] ORDER TO EXTEND DEADLINE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG. (Pogue, David) (Entered: 04/17/2025) (2) |
| Apr 16, 2025 | 319 | STIPULATION AND [PROPOSED] ORDER TO EXTEND DEADLINE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG. (Pogue, David) (Entered: 04/16/2025) (2) |
| Apr 9, 2025 | 312 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition of Patrick Romer). (O'Brien, William) (Entered: 04/09/2025) (1) |
| Apr 9, 2025 | 313 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition of Gerd Seiffert). (O'Brien, William) (Entered: 04/09/2025) (1) |
| Apr 9, 2025 | 314 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition of Thomas Klein). (O'Brien, William) (Entered: 04/09/2025) (1) |
| Apr 9, 2025 | 315 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition of Eva Ulrike Graefe-Mody). (O'Brien, William) (Entered: 04/09/2025) (1) |
| Apr 9, 2025 | 316 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition of Anja Kohlrausch). (O'Brien, William) (Entered: 04/09/2025) (1) |
| Apr 9, 2025 | 317 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition of Michael Mark). (O'Brien, William) (Entered: 04/09/2025) (1) |
| Apr 9, 2025 | 318 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition of Hans-Juergen Woerle). (O'Brien, William) (Entered: 04/09/2025) (1) |
| Apr 8, 2025 | 306 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Mylan's First Set of Requests for Documents and Things to Plaintiffs (Nos. 1-66)). (O'Brien, William) (Entered: 04/08/2025) (1) |
| Apr 8, 2025 | 307 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Mylan's First Set of Interrogatories to Plaintiffs (Nos. 1-13)). (O'Brien, William) (Entered: 04/08/2025) (1) |
| Apr 8, 2025 | 308 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Mylan Defendants' Initial Invalidity Contentions). (O'Brien, William) (Entered: 04/08/2025) (1) |
| Apr 8, 2025 | 309 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6)). (O'Brien, William) (Entered: 04/08/2025) (1) |
| Apr 8, 2025 | 310 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Mylan's Preliminary Responses to Plaintiffs' Infringement Contentions for U.S. Patent Nos. 11,033,552 and 11,911,388). (O'Brien, William) (Entered: 04/08/2025) (1) |
| Apr 8, 2025 | 311 | CERTIFICATE OF SERVICE by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited (Mylan's Responses and Objections to Plaintiffs' Notice of 30(b)(6) Deposition). (O'Brien, William) (Entered: 04/08/2025) (1) |
| Apr 7, 2025 | 305 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Objections and Responses to Defendants' Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6). (Pogue, David) (Entered: 04/07/2025) (1) |
| Apr 3, 2025 | 304 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Response to Defendants' Invalidity Contentions. (Pogue, David) (Entered: 04/03/2025) (1) |
| Mar 31, 2025 | 303 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' First Supplemental Responses and Objections to Mylan's First Set of Interrogatories (No. 6). (Pogue, David) (Entered: 03/31/2025) (1) |
| Mar 27, 2025 | 298 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Requests for Admission (Nos. 41-80) to Defendants Mylan Pharmaceuticals Inc., Mylan Inc., and Mylan Laboratories Limited. (Pogue, David) (Entered: 03/27/2025) (1) |
| Mar 27, 2025 | 299 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Second Set of Interrogatories to Mylan (Nos. 12-23). (Pogue, David) (Entered: 03/27/2025) (1) |
| Mar 27, 2025 | 300 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Notice of 30(b)(1) Deposition of Ashish Jaiswal. (Pogue, David) (Entered: 03/27/2025) (1) |
| Mar 27, 2025 | 301 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Notice of 30(b)(1) Deposition of Katie Reed. (Pogue, David) (Entered: 03/27/2025) (1) |
| Mar 27, 2025 | 302 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Notice of 30(b)(1) Deposition of Ritesh Kakaria. (Pogue, David) (Entered: 03/27/2025) (1) |
| Mar 25, 2025 | 295 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Responses and Objections to Mylans First Set of Interrogatories to Plaintiffs (Nos. 1-13). (Pogue, David) (Entered: 03/25/2025) (1) |
| Mar 25, 2025 | 296 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Response to Mylan's First Set of Requests for Documents and Things to Plaintiffs (Nos. 1-66). (Pogue, David) (Entered: 03/25/2025) (1) |
| Mar 25, 2025 | 297 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Notice of 30(b)(6) Deposition of Mylan Pharmaceuticals Inc., Mylan Inc., and Mylan Laboratories Ltd.. (Pogue, David) (Entered: 03/25/2025) (1) |
| Mar 18, 2025 | 291 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Notice of Deposition of Beth Britton. (Pogue, David) (Entered: 03/18/2025) (1) |
| Mar 18, 2025 | 292 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Notice of 30(b)(1) Deposition of Santanu Chakraborty. (Pogue, David) (Entered: 03/18/2025) (1) |
| Mar 18, 2025 | 293 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Notice of 30(b)(1) Deposition of Shane Shupe. (Pogue, David) (Entered: 03/18/2025) (1) |
| Mar 18, 2025 | 294 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG for Plaintiffs' Notice of 30(b)(1) Deposition of V. Naga Prasad. (Pogue, David) (Entered: 03/18/2025) (1) |
| Mar 14, 2025 | 290 | ORDER ADOPTING JOINT AMENDED CASE SCHEDULE: Discovery due by 4/25/2025. Proposed Pretrial Order due by 7/28/2025. Final Pretrial Conference set for 8/4/2025 01:20 PM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S. Kleeh. Bench Trial set for 8/25/2025 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S. Kleeh (5 days reserved). Signed by Chief District Judge Thomas S. Kleeh on 03/14/2025. (snc) (Entered: 03/14/2025) (3) |
| Mar 5, 2025 | 289 | Other Document JOINT AMENDED CASE SCHEDULE filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG. (Pogue, David) (Entered: 03/05/2025) (9) |
| Feb 28, 2025 | 288 | ORDER GRANTING MOTION TO WITHDRAW AS COUNSEL (ECF NO. 287 ). Attorney John D. Pizzo terminated. Signed by Chief District Judge Thomas S. Kleeh on 02/28/2025. (snc) (Entered: 02/28/2025) (1) |
| Feb 26, 2025 | 287 | MOTION to Withdraw as Attorney (John D. Pizzo) by Mylan Pharmaceuticals Inc., Mylan Inc., Mylan Laboratories Limited. (O'Brien, William) (Entered: 02/26/2025) (2) |
| Feb 21, 2025 | 285 | ORDER CONSOLIDATING ACTIONS AND RESCHEDULING PRETRIAL CONFERENCE AND TRIAL. The above-captioned cases are CONSOLIDATED, with Case No. 1:20-CV-19 designated as the LEAD CASE. The parties and the Clerk are DIRECTED to file all documents in the lead case. The motion for status conference in Case No. 1:24cv82 is DENIED AS MOOT (ECF No. 55 ). Pretrial Conference set for 8/4/2025 01:30 PM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Bench Trial set for 8/25/2025 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh (5 days reserved). Signed by Chief District Judge Thomas S Kleeh on 2/21/2025. (dk) (Entered: 02/21/2025) (2) |
| Feb 21, 2025 | 286 | Request to Discontinue E-mail Notification. (Morgan, Shawn) (Entered: 02/21/2025) (0) |
| Feb 12, 2025 | 284 | ORDER. The Court has determined that the motion for status conference ECF No. 258 should be, and hereby is, DENIED AS MOOT. Signed by Chief District Judge Thomas S Kleeh on 2/12/2025. (mas) (Entered: 02/12/2025) (1) |
| Nov 22, 2024 | 283 | Corporate Disclosure Statement by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. identifying Corporate Parent C.H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc... (Pogue, David) (Main Document 283 replaced with flattened document on 11/25/2024) (snc). (Entered: 11/22/2024) (2) |
| Nov 18, 2024 | 282 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs' Notice of Deposition of Santanu Chakraborty. (Pogue, David) (Entered: 11/18/2024) (1) |
| Nov 15, 2024 | 280 | ORDER granting 276 Motion for Leave to Appear Pro Hac Vice (Eliana Applebaum). Signed by Chief District Judge Thomas S. Kleeh on 11/15/2024. (snc) (Entered: 11/15/2024) (1) |
| Nov 15, 2024 | 281 | ORDER granting 277 Motion for Leave to Appear Pro Hac Vice (Christopher Ilardi). Signed by Chief District Judge Thomas S. Kleeh on 11/15/2024. (snc) (Entered: 11/15/2024) (1) |
| Nov 14, 2024 | 276 | MOTION for Leave to Appear Pro Hac Vice of Eliana Applebaum by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment A, # 2 Exhibit A-WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 11/14/2024) (0) |
| Nov 14, 2024 | 277 | MOTION for Leave to Appear Pro Hac Vice of Christopher Ilardi by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment A, # 2 Exhibit A-WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 11/14/2024) (0) |
| Nov 14, 2024 | 278 | Request to Discontinue E-mail Notification. (Morgan, Shawn) (Entered: 11/14/2024) (0) |
| Nov 14, 2024 | 279 | Pro Hac Vice filing fee for Christopher Ilardi and Eliana Applebaum in the amount of $400.00 paid. Receipt Number: 100003970. (jb) (Entered: 11/14/2024) (0) |
| Nov 6, 2024 | 275 | Request to Discontinue E-mail Notification. (Morgan, Shawn) (Entered: 11/06/2024) (0) |
| Nov 5, 2024 | 273 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs Third Supplemental Response to Mylans First Joint Set of Interrogatories to Plaintiffs (Nos. 1-4, 6-8, 10-14, 18-20). (Pogue, David) (Entered: 11/05/2024) (1) |
| Nov 5, 2024 | 274 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. CORRECTED CERTIFICATE OF SERVICE for Plaintiffs' Third Supplemental Response to Mylan's First Joint Set of Interrogatories to Plaintiffs (Nos. 1-4, 6-8, 10-14, 18-20). (Pogue, David) (Entered: 11/05/2024) (1) |
| Oct 10, 2024 | 272 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. FOR PLAINTIFFS' NOTICE OF DEPOSITION OF DEFENDANTS MYLAN PHARMACEUTICALS INC., MYLAN LABORATORIES LIMITED, AND MYLAN INC. (Pogue, David) (Entered: 10/10/2024) (1) |
| Oct 7, 2024 | 270 | ORDER granting 244 Motion for Leave to Appear Pro Hac Vice as to Matthew Holub filed by Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S. Kleeh on 10/7/2024. (jb) (Entered: 10/07/2024) (1) |
| Oct 7, 2024 | 271 | ORDER granting 243 Motion for Leave to Appear Pro Hac Vice as to (Jitendra Malik) filed by Mylan Laboratories Limited, Mylan Inc., Mylan Pharmaceuticals Inc. Signed by Chief District Judge Thomas S Kleeh on 10/7/2024. (mas) (Entered: 10/07/2024) (1) |
| Sep 20, 2024 | 269 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs' Second Set of Interrogatories to Mylan (Nos. 11-22). (Pogue, David) (Entered: 09/20/2024) (1) |
| Aug 28, 2024 | 268 | JOINT STIPULATION AND ORDER TO MODIFY SCHEDULE. (Pretrial Order due by 4/2/2025, Final Pretrial Conference set for 4/9/2025 at 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S. Kleeh, Bench Trial set for 4/14/2025 at 09:30 AM (5 days reserved) in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S. Kleeh.) Signed by Chief District Judge Thomas S. Kleeh on 08/28/2024. (snc) (Entered: 08/28/2024) (4) |
| Aug 20, 2024 | 266 | STIPULATION AND [PROPOSED] ORDER TO MODIFY SCHEDULE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Pogue, David) (Entered: 08/20/2024) (4) |
| Aug 20, 2024 | 267 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 8.7.24 and 8.16.24). (O'Brien, William) (Entered: 08/20/2024) (2) |
| Aug 14, 2024 | 265 | Request to Discontinue E-mail Notification. (Morgan, Shawn) (Entered: 08/14/2024) (0) |
| Aug 13, 2024 | 263 | ***SEALED*** ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 262 ). Signed by Chief District Judge Thomas S. Kleeh on 08/13/2024. (Copy to counsel by email) (snc) (Entered: 08/13/2024) (0) |
| Aug 8, 2024 | 261 | MEMORANDUM IN OPPOSITION TO PLAINTIFFS' MOTION FOR CONTINUANCE REGARDING EXPERT DISCOVERY AND TRIAL AND MOTION FOR EXPEDITED BRIEFING SCHEDULE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. . (O'Brien, William) (Entered: 08/08/2024) (15) |
| Aug 6, 2024 | 259 | ORDER GRANTING MOTION TO SEAL. The pending motion to seal is GRANTED 257 . Signed by Chief District Judge Thomas S. Kleeh on 08/06/2024. (snc) (Entered: 08/06/2024) (1) |
| Aug 6, 2024 | 260 | ORDER. Defendants are DIRECTED to file a response to Plaintiffs' motion for continuance [257-2] on or before August 8, 2024. Plaintiffs are DIRECTED to file a reply on or before August 12, 2024. Signed by Chief District Judge Thomas S. Kleeh on 08/06/2024. (snc) (Entered: 08/06/2024) (1) |
| Jul 29, 2024 | 258 | MOTION FOR STATUS CONFERENCE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Pogue, David) (Entered: 07/29/2024) (3) |
| Jul 26, 2024 | 254 | NOTICE of Appearance by Steven Robert Ruby on behalf of Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (Ruby, Steven) (Entered: 07/26/2024) (2) |
| Jul 26, 2024 | 255 | NOTICE of Appearance by David R. Pogue on behalf of Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (Pogue, David) (Entered: 07/26/2024) (2) |
| Jul 26, 2024 | 256 | NOTICE of Appearance by Jordan Lee Damron on behalf of Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (Damron, Jordan) (Entered: 07/26/2024) (2) |
| Jun 16, 2024 | 253 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Rebuttal Expert Reports of Dr. Biggs and Dr. Banakar). (O'Brien, William) (Entered: 06/16/2024) (1) |
| Jun 13, 2024 | 252 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs' Rebuttal Expert Reports of Mitchell Rosner, Mark Warren, James A. Bristol and Mansoor Amiji. (Law, Sandra) (Entered: 06/13/2024) (2) |
| Jun 10, 2024 | 251 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiff's Second Supplemental Response to Mylan's First Joint Set of Interrogatories. (Law, Sandra) (Entered: 06/10/2024) (2) |
| May 21, 2024 | 250 | JOINT STIPULATION AND ORDER TO MODIFY SCHEDULE. Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. (snc) (Entered: 05/21/2024) (3) |
| May 20, 2024 | 249 | STIPULATION Joint Stipulation To Modify Schedule by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Law, Sandra) (Entered: 05/20/2024) (3) |
| Apr 25, 2024 | 247 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 04/25/2024. (Copy to counsel) (snc) (Entered: 04/25/2024) (0) |
| Apr 22, 2024 | 245 | Pro Hac Vice Filing Fee in the amount of $400.00 paid for Jitendra Malik and Matthew Holub. Receipt Number: 100003881. (jb) (Entered: 04/22/2024) (0) |
| Apr 19, 2024 | 244 | MOTION for Leave to Appear pro hac vice Matthew Holub by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 04/19/2024) () (3) |
| Apr 19, 2024 | 244 | MOTION for Leave to Appear pro hac vice Matthew Holub by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 04/19/2024) (Proposed Order) (1) |
| Apr 17, 2024 | 243 | MOTION for Leave to Appear Pro Hac Vice (Jitendra Malik) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/17/2024) () (3) |
| Apr 17, 2024 | 243 | MOTION for Leave to Appear Pro Hac Vice (Jitendra Malik) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/17/2024) (Proposed Order) (1) |
| Apr 16, 2024 | 242 | STIPULATION AND ORDER TO EXTEND DEADLINE. (Replies due by 4/24/2024.) Signed by Chief District Judge Thomas S. Kleeh on 04/16/2024. (snc) (Entered: 04/16/2024) (2) |
| Apr 15, 2024 | 241 | STIPULATION and proposed Order to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Law, Sandra) (Entered: 04/15/2024) (2) |
| Apr 11, 2024 | 239 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 04/11/2024. (Copy to counsel) (snc) (Entered: 04/11/2024) (0) |
| Apr 8, 2024 | 237 | ORDER GRANTING MOTION TO WITHDRAW AS COUNSEL [ECF NO. 236 ]. Attorney Andrew Walter is hereby terminated from the case. Signed by Chief District Judge Thomas S. Kleeh on 4/8/2024. (jb) (Entered: 04/08/2024) (2) |
| Apr 5, 2024 | 236 | MOTION to Withdraw as Attorney for Andrew Walter by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order Granting Motion to Withdraw)(Law, Sandra) (Entered: 04/05/2024) () (3) |
| Apr 5, 2024 | 236 | MOTION to Withdraw as Attorney for Andrew Walter by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order Granting Motion to Withdraw)(Law, Sandra) (Entered: 04/05/2024) (Proposed Order Granting Motion to Withdraw) (2) |
| Apr 2, 2024 | 235 | ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 4/2/2024. Copy to counsel.(cmd) (Entered: 04/02/2024) (0) |
| Apr 1, 2024 | 234 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs' Opening Expert Reports. (Law, Sandra) (Entered: 04/01/2024) (2) |
| Mar 27, 2024 | 233 | MOTION to Strike Late-Disclosed Portions of Defendants' Final Invalidity Contentions by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Plaintiffs' Motion to Strike Late-Disclosed Portions of Defendant's Final Invalidity Contentions, # 2 Attachment Plaintiffs' Memoranda in Support of Motion to Strike Late Disclosed Portions of Defendant's Final Invalidity Contentions, # 3 Attachment Declaration of Sandra K. Law in Support of Motion to Strike Late-Disclosed Portions of Defendant's Final Invalidity Contentions, # 4 Exhibit 1 to Law Declaration, # 5 Exhibit 2 to Law Declaration, # 6 Exhibit 3 to Law Declaration, # 7 Exhibit 4 to Law Declaration, # 8 Exhibit 5 to Law Declaration, # 9 Exhibit 6 to Law Declaration, # 10 Exhibit 7 to Law Declaration, # 11 Exhibit 8 to Law Declaration, # 12 Exhibit 9 to Law Declaration, # 13 Exhibit 10 to Law Declaration, # 14 Exhibit 11 to Law Declaration, # 15 Exhibit 12 to Law Declaration, # 16 Exhibit 13 to Law Declaration, # 17 Exhibit 14 to Law Declaration, # 18 Exhibit 15 to Law Declaration, # 19 Exhibit 16 to Law Declaration, # 20 Exhibit 17 to Law Declaration, # 21 Exhibit 18 to Law Declaration, # 22 Exhibit 19 to Law Declaration, # 23 Exhibit 20 to Law Declaration, # 24 Exhibit 21 to Law Declaration, # 25 Exhibit 22 to Law Declaration, # 26 Exhibit 23 to Law Declaration, # 27 Exhibit 24 to Law Declaration, # 28 Exhibit 25 to Law Declaration, # 29 Exhibit 26 to Law Declaration, # 30 Exhibit 27 to Law Declaration, # 31 Exhibit 28 to Law Declaration, # 32 Exhibit 29 to Law Declaration, # 33 Exhibit 30 to Law Declaration, # 34 Exhibit 31 to Law Declaration)(Law, Sandra) Modified on 4/2/2024 (cmd). (Entered: 03/27/2024) (0) |
| Feb 12, 2024 | 232 | AMENDED SCHEDULING ORDER: Joint Final Pre-trial Order due by 9/13/2024. Final Pre-trial Conference set for 10/7/2024 at 11:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Bench Trial set for 10/21/2024 09:30 AM (5 days reserved) in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 2/12/2024. (snc) (Entered: 02/12/2024) (2) |
| Feb 9, 2024 | 231 | Stipulation and [Proposed] Order to Modify Schedule ( Other Document ) filed by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/09/2024) (4) |
| Feb 7, 2024 | 230 | TRANSCRIPT of Proceedings held on April 27, 2020, before Senior Judge Irene M. Keeley. Court Reporter/Transcriber Stacy Harlow. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 2/28/2024. Redacted Transcript Deadline set for 3/11/2024. Release of Transcript Restriction set for 5/7/2024. (kac) (Entered: 02/07/2024) (27) |
| Jan 30, 2024 | 228 | TRANSCRIPT of Status Conference held on 5/9/2022 before Judge Thomas S. Kleeh. Court Reporter/Transcriber Rachel Kocher, Telephone number (304) 623-7179. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 2/20/2024. Redacted Transcript Deadline set for 3/1/2024. Release of Transcript Restriction set for 4/29/2024. (rak) (Entered: 01/30/2024) (10) |
| Jan 30, 2024 | 229 | TRANSCRIPT of Status Conference held on 4/12/2023 before Judge Thomas S. Kleeh. Court Reporter/Transcriber Rachel Kocher, Telephone number (304) 623-7179. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 2/20/2024. Redacted Transcript Deadline set for 3/1/2024. Release of Transcript Restriction set for 4/29/2024. (rak) (Entered: 01/30/2024) (7) |
| Jan 25, 2024 | 227 | TRANSCRIPT of status conference held on 9/15/2021, before Judge Keeley. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 2/15/2024. Redacted Transcript Deadline set for 2/26/2024. Release of Transcript Restriction set for 4/24/2024. (ck) (Entered: 01/25/2024) (7) |
| Jan 16, 2024 | 226 | STIPULATION AND ORDER TO MODIFY SCHEDULE. Signed by Chief District Judge Thomas S Kleeh on 01/16/2024. (snc) (Entered: 01/16/2024) (3) |
| Jan 11, 2024 | 225 | STIPULATION and Proposed Order by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 01/11/2024) (3) |
| Dec 29, 2023 | 224 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Final Invalidity Contentions). (O'Brien, William) (Entered: 12/29/2023) (1) |
| Dec 1, 2023 | 223 | ORDER TO MODIFY SCHEDULE. Signed by Chief District Judge Thomas S Kleeh on 12/01/2023. (snc) (Entered: 12/01/2023) (3) |
| Nov 30, 2023 | 222 | STIPULATION and Proposed Order to Modify Schedule, not affecting trial and pretrial dates by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Copland, Gordon) (Entered: 11/30/2023) (3) |
| Oct 23, 2023 | 220 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Final Contentions Against Mylan for its ANDA Product Associated with ANDA No. 208431 for U.S. Patent No. 9,486,526 and Against Mylan for its ANDA Product Associated with ANDA No. 208431 for U.S. Patents Nos. 9,415,016 and 10,022,379 (Companion, James) (Entered: 10/23/2023) (2) |
| Oct 23, 2023 | 221 | TRANSCRIPT of claim construction hearing held on 2/10/2021, before Judge Keeley. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 11/13/2023. Redacted Transcript Deadline set for 11/24/2023. Release of Transcript Restriction set for 1/22/2024. (ck) (Entered: 10/23/2023) (73) |
| Oct 4, 2023 | 219 | SCHEDULING ORDER: Close of Fact Discovery due by 8/31/2023. Close of Expert Discovery due by 5/17/2024. Joint Final Pretrial Order due by 8/9/2024. Final Pretrial Conference set for 9/5/2024 12:30 PM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Bench Trial set for 10/21/2024 09:30 AM (5 days reserved) in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 10/04/2023. (snc) (Entered: 10/04/2023) (2) |
| Sep 1, 2023 | 218 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories to Mylan). (O'Brien, William) (Entered: 09/01/2023) (2) |
| Jun 30, 2023 | 217 | Other Document Joint Proposed Schedule filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Law, Sandra) (Entered: 06/30/2023) (6) |
| Apr 12, 2023 | 211 | ORDER DENYING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE ECF NO. 210 . Signed by Chief District Judge Thomas S Kleeh on 4/12/2023. (snc) (Entered: 04/12/2023) (1) |
| Apr 12, 2023 | 212 | MOTION for Leave to Appear Pro Hac Vice for Ashley Ross by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 04/12/2023) (Main Document) (2) |
| Apr 12, 2023 | 213 | ORDER. The parties are ORDERED to submit, on or before June 30, 2023, a joint proposed schedule to govern the case moving forward or an advisement as to why a joint proposed schedule could not be submitted. Signed by Chief District Judge Thomas S Kleeh on 4/12/2023. (snc) (Entered: 04/12/2023) (1) |
| Apr 12, 2023 | 214 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh: Status Conference held on 4/12/2023. (Court Reporter Rachel Kocher.) (jb) (Entered: 04/12/2023) (0) |
| Apr 12, 2023 | 215 | Pro Hac Vice filing fee for Ashley Ross in the amount of $200.00 paid. Receipt Number WVNC003675. (jb) (Entered: 04/12/2023) (0) |
| Apr 12, 2023 | 216 | ORDER granting 212 Motion for Leave to Appear Pro Hac Vice for Ashley Ross filed by Boehringer Ingelheim Corporation. Signed by Chief District Judge Thomas S Kleeh on 4/12/2023. (jb) NEF reg on 4/21/2023 (jb). (Entered: 04/12/2023) (1) |
| Apr 12, 2023 | 212 | MOTION for Leave to Appear Pro Hac Vice for Ashley Ross by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 04/12/2023) (Proposed Order) (1) |
| Apr 11, 2023 | 210 | Joint MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/11/2023) (Main Document) (3) |
| Apr 11, 2023 | 210 | Joint MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE by Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/11/2023) (Proposed Order) (1) |
| Jan 5, 2023 | 209 | ORDER GRANTING 208 JOINT MOTION TO RESCHEDULE STATUS CONFERENCE. Status Conference set for 4/12/2023 01:30 PM before Chief District Judge Thomas S Kleeh. The status conference will be conducted via ZoomGov video conference with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 1/5/2023. (dk) (Entered: 01/05/2023) (2) |
| Jan 4, 2023 | 208 | Joint Motion Requesting Rescheduling of Status Conference filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra). Wrong Event Used. Modified to make pending motion on 1/5/2023. NEF regen (dk). (Entered: 01/04/2023) (Main Document) (2) |
| Jan 4, 2023 | 208 | Joint Motion Requesting Rescheduling of Status Conference filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra). Wrong Event Used. Modified to make pending motion on 1/5/2023. NEF regen (dk). (Entered: 01/04/2023) (Proposed Order) (1) |
| Oct 14, 2022 | 207 | ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 1/9/2023 01:30 PM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 10/14/2022. (dk) (Main Document 207 replaced with corrected document on 10/14/2022. NEF regen) (dk). (Entered: 10/14/2022) (2) |
| Oct 11, 2022 | 206 | ORDER GRANTING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE (ECF. NO. 205 ). For good cause shown, the motion is GRANTED [ECF No. 205]. The status conference is GENERALLY CONTINUED and will be rescheduled by separate order. Signed by Chief District Judge Thomas S Kleeh on 10/11/2022. (dk) (Entered: 10/11/2022) (1) |
| Oct 10, 2022 | 205 | Joint MOTION Requesting Rescheduling of Status Conference re 204 Order, Set/Reset Hearings by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/10/2022) (Main Document) (2) |
| Oct 10, 2022 | 205 | Joint MOTION Requesting Rescheduling of Status Conference re 204 Order, Set/Reset Hearings by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/10/2022) (Proposed Order) (1) |
| Aug 17, 2022 | 204 | ORDER. Status Conference, by Zoom videoconferencing, set for 10/12/2022 01:30 PM, in Judge Kleeh Chambers before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 8/17/2022. (dk) (Entered: 08/17/2022) (1) |
| Aug 11, 2022 | 202 | Joint MOTION Requesting Rescheduling of Status Conference re 201 Order Cancelling Deadline,, Set/Reset Hearings, by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 08/11/2022) (Main Document) (2) |
| Aug 11, 2022 | 203 | ORDER GRANTING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE (ECF. NO. 202 ). The status conference is GENERALLY CONTINUED and will be rescheduled by separate order. Signed by Chief District Judge Thomas S Kleeh on 8/11/2022. (dk) (Entered: 08/11/2022) (1) |
| Aug 11, 2022 | 202 | Joint MOTION Requesting Rescheduling of Status Conference re 201 Order Cancelling Deadline,, Set/Reset Hearings, by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 08/11/2022) (Proposed Order) (1) |
| Aug 4, 2022 | 201 | ORDER RESCHEDULING STATUS CONFERENCE: The status conference is RESCHEDULED to August 15, 2022, at 2:45 p.m. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 8/4/22. (jss) (Entered: 08/04/2022) (2) |
| Jul 11, 2022 | 200 | ORDER RESCHEDULING STATUS CONFERENCE for 8/18/2022 11:00 AM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 7/11/2022. (dk) (Entered: 07/11/2022) (2) |
| Jul 8, 2022 | 199 | ORDER GRANTING JOINT MOTION REQUESTING RESCHEDULING OF STATUS CONFERENCE: The 198 Motion to Continue is GRANTED. The July 11, 2022 Status Conference is GENERALLY CONTINUED. Signed by Chief District Judge Thomas S Kleeh on 7/8/2022. (cnd) (Entered: 07/08/2022) (1) |
| Jul 7, 2022 | 198 | Joint MOTION to Continue Requesting Rescheduling of Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 07/07/2022) (Main Document) (2) |
| Jul 7, 2022 | 198 | Joint MOTION to Continue Requesting Rescheduling of Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 07/07/2022) (Proposed Order) (1) |
| May 9, 2022 | 196 | ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 7/11/2022 12:30 PM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 5/9/2022. (dk) (Entered: 05/09/2022) (2) |
| May 9, 2022 | 197 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh. Status Conference held on 5/9/2022. (Court Reporter Rachel Kocher.) (wrr) (Entered: 05/09/2022) (0) |
| May 2, 2022 | 195 | ORDER RESCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 5/9/2022 11:00 AM before Chief District Judge Thomas S Kleeh. The parties can access the status conference via ZoomGov video conferencing with an option to participate telephonically. Signed by Chief District Judge Thomas S Kleeh on 5/2/2022. (dk) (Entered: 05/02/2022) (2) |
| Apr 25, 2022 | 194 | ORDER RESCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 5/5/2022 10:30 AM before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 4/25/2022. (dk) (Entered: 04/25/2022) (2) |
| Apr 5, 2022 | 192 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. for NOTICE OF DEPOSITION OF MICHAEL BRAUN. (Copland, Gordon) (Entered: 04/05/2022) (2) |
| Apr 5, 2022 | 193 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. for NOTICE OF DEPOSITION OF EVA ULRIKE GRAEFE-MODY. (Copland, Gordon) (Entered: 04/05/2022) (2) |
| Feb 10, 2022 | 190 | MOTION to Withdraw as Attorney of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2022) (Main Document) (3) |
| Feb 10, 2022 | 191 | ORDER granting 190 Motion to Withdraw as Attorney. Attorney Mira Atanassova Mulvaney terminated. Signed by District Judge Thomas S. Kleeh on 2/10/22. (jss) (Entered: 02/10/2022) (1) |
| Feb 10, 2022 | 190 | MOTION to Withdraw as Attorney of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2022) (Proposed Order) (1) |
| Feb 4, 2022 | 189 | TRANSCRIPT of Proceedings held on January 24, 2022, before Judge Thomas S. Kleeh. Court Reporter/Transcriber Lisa A. Cook, RPR-RMR-CRR-FCRR, Telephone number 304-347-3198. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days. Redaction Request due 2/25/2022. Redacted Transcript Deadline set for 3/7/2022. Release of Transcript Restriction set for 5/5/2022. (kac) (Entered: 02/04/2022) (13) |
| Jan 24, 2022 | 187 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before District Judge Thomas S. Kleeh: Status Conference held on 1/24/2022. (Court Reporter Lisa Cook.) (jmm) (Entered: 01/24/2022) (0) |
| Jan 24, 2022 | 188 | ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE for 4/28/2022 11:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before District Judge Thomas S. Kleeh. Signed by District Judge Thomas S. Kleeh on 1/24/2022. (dk) (Entered: 01/24/2022) (2) |
| Nov 10, 2021 | 186 | ORDER granting 181 Motion to Withdraw : Attorney Guylaine Hache terminated. Signed by District Judge Thomas S. Kleeh on 11/10/21. (jss) (Entered: 11/10/2021) (1) |
| Oct 27, 2021 | 185 | ORDER GRANTING IN PART MOTION TO EXTEND DEADLINES AND SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE: The Court GRANTS the motion to extend the Close of Fact Discovery deadline to January 14, 2022. The Court DENIES the adoption of the agreed schedule outlined in the motion, and, rather, CONTINUES all other deadlines pending in this matter. The Court SCHEDULES a status conference forJanuary 24, 2022, at 11:00 a.m. Signed by District Judge Thomas S. Kleeh on 10/27/21. (jss) (Entered: 10/27/2021) (2) |
| Oct 26, 2021 | 183 | Pro Hac Vice Filing fee for Sam Kwon: $ 200.00, receipt number WVNC003390 (jss) (Entered: 10/26/2021) (0) |
| Oct 26, 2021 | 184 | ORDER granting 180 Motion for Leave to Appear pro hac vice of Sam Kwon. Signed by District Judge Thomas S. Kleeh on 10/26/21. (jss) (Entered: 10/26/2021) (1) |
| Oct 22, 2021 | 182 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before District Judge Thomas S. Kleeh: Status Conference held on 10/22/2021. (Court Reporter Jill Cutter.) (jmm) (Entered: 10/22/2021) (0) |
| Oct 21, 2021 | 180 | MOTION for Leave to Appear Pro Hac Vice of Sam Kwon by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/21/2021) (Main Document) (2) |
| Oct 21, 2021 | 181 | MOTION to Withdraw as Attorney for Guylaine Hache by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 10/21/2021) (Main Document) (3) |
| Oct 21, 2021 | 181 | MOTION to Withdraw as Attorney for Guylaine Hache by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Copland, Gordon) (Entered: 10/21/2021) (Proposed Order) (1) |
| Oct 21, 2021 | 180 | MOTION for Leave to Appear Pro Hac Vice of Sam Kwon by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 10/21/2021) (Proposed Order) (1) |
| Oct 20, 2021 | 179 | ORDER RESCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE to 10/22/2021 11:30 AM in Judge Kleeh Chambers before District Judge Thomas S. Kleeh. Signed by District Judge Thomas S. Kleeh on 10/20/2021. (dk) (Entered: 10/20/2021) (2) |
| Sep 23, 2021 | 177 | Joint MOTION Requesting Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 09/23/2021) (Main Document) (2) |
| Sep 23, 2021 | 178 | ORDER SCHEDULING STATUS CONFERENCE BY VIDEOCONFERENCE granting 177 Motion. Status Conference set for 10/21/2021 10:00 AM before District Judge Thomas S. Kleeh. Signed by District Judge Thomas S. Kleeh on 9/23/21. (mh) (Entered: 09/23/2021) (2) |
| Sep 23, 2021 | 177 | Joint MOTION Requesting Status Conference by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 09/23/2021) (Proposed Order) (1) |
| Sep 15, 2021 | 175 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Status Conference held on 9/15/2021. (Court Reporter Cindy Knecht) (dk) (Entered: 09/15/2021) (0) |
| Sep 15, 2021 | 176 | ORDER TRANSFERRING CASE. Case reassigned to District Judge Thomas S. Kleeh for all further proceedings. Senior Jud. ge Irene M. Keeley no longer assigned to case Signed by Senior Judge Irene M. Keeley on 9/15/21. (mh) (Entered: 09/15/2021) (1) |
| Sep 14, 2021 | 172 | TRANSCRIPT of status conference held on 8/16/2021, before Judge Keeley. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 10/5/2021. Redacted Transcript Deadline set for 10/15/2021. Release of Transcript Restriction set for 12/13/2021. (ck) (Entered: 09/14/2021) (12) |
| Sep 14, 2021 | 173 | TRANSCRIPT PURCHASE ORDER by Boehringer Ingelheim Corporation for proceedings held on 8/16/2021 before Judge Keeley. (ck) (Entered: 09/14/2021) (2) |
| Sep 14, 2021 | 174 | TRANSCRIPT PURCHASE ORDER by Mylan Inc. for proceedings held on 8/16/2021 before Judge Keeley. (ck) (Entered: 09/14/2021) (2) |
| Sep 9, 2021 | 171 | ORDER SCHEDULING STATUS CONFERENCE: The Court SCHEDULES a status conference for Wednesday, September 15, 2021, at 1:00 P.M. Signed by Senior Judge Irene M. Keeley on 9/9/21. (jss) (Entered: 09/09/2021) (1) |
| Aug 16, 2021 | 170 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Status Conference held on 8/16/2021. (Court Reporter Cindy Knecht) (dk) (Entered: 08/16/2021) (0) |
| Jul 27, 2021 | 169 | ORDER SCHEDULING STATUS CONFERENCE for 8/16/2021 11:30 AM via zoom before Senior Judge Irene M. Keeley. Signed by Senior Judge Irene M. Keeley on 7/27/21. (mh) (Entered: 07/27/2021) (1) |
| Jul 23, 2021 | 166 | Other Document Notice of Withdrawal of Plaintiffs' Motion to Seal filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Certificate of Service)(Companion, James) (Entered: 07/23/2021) (Main Document) (2) |
| Jul 23, 2021 | 167 | Unopposed Motion to Extend Deadlines filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) Modified on 7/23/2021 - corrected event type (jss). (Entered: 07/23/2021) (7) |
| Jul 23, 2021 | 168 | ORDER DENYING AS MOOT MOTION FOR LEAVE TO FILE UNDER SEAL (DKT. NO. 161 ). Signed by Senior Judge Irene M. Keeley on 7/23/21. (mh) (Entered: 07/23/2021) (1) |
| Jul 23, 2021 | 166 | Other Document Notice of Withdrawal of Plaintiffs' Motion to Seal filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Certificate of Service)(Companion, James) (Entered: 07/23/2021) (Attachment Certificate of Service) (2) |
| Jul 19, 2021 | 162 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced 07/16/2021 (Companion, James) (Entered: 07/19/2021) (2) |
| Jul 19, 2021 | 163 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Supplemental Response to Mylan's First Joint Set of Interrogatories to Plaintiffs (Nos. 1-8, 17) (Companion, James) (Entered: 07/19/2021) (2) |
| Jul 19, 2021 | 164 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Rule 26(a) Second Supplemental Initial Disclosure Statement (Companion, James) (Entered: 07/19/2021) (2) |
| Jul 19, 2021 | 165 | ORDER DIRECTING PLAINTIFFS TO SUPPLEMENT MOTION FOR LEAVE TO FILE UNDER SEAL [DKT. NO. 161 . The Court DIRECTS Boehringer, by Monday, July 26,2021, to supplement their motion to seal with additional information and authority. Signed by Senior Judge Irene M. Keeley on 7/19/21. (jss) (Entered: 07/19/2021) (4) |
| Jul 8, 2021 | 157 | MOTION for Leave to Appear Pro Hac Vice of Andrew Walter by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 07/08/2021) (Main Document) (2) |
| Jul 8, 2021 | 158 | Pro Hac Vice Filing fee for Andrew Walter: $ 200.00, receipt number WVNC003227 (jss) (Entered: 07/08/2021) (0) |
| Jul 8, 2021 | 159 | ORDER granting Andrew Walter's 157 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 7/8/21. (jss) (Entered: 07/08/2021) (1) |
| Jul 8, 2021 | 160 | MEMORANDUM OPINION AND ORDER ADOPTING PLAINTIFFS PROPOSED CLAIM CONSTRUCTION. Signed by Senior Judge Irene M. Keeley on 7/8/21. (jss) (Entered: 07/08/2021) (22) |
| Jul 8, 2021 | 157 | MOTION for Leave to Appear Pro Hac Vice of Andrew Walter by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 07/08/2021) (Proposed Order) (1) |
| Jul 2, 2021 | 152 | Proposed Consent Judgment Order re Aurobindo Pharma Ltd. by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 07/02/2021) (4) |
| Jul 2, 2021 | 153 | CONSENT JUDGMENT re Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. and Aurobindo Pharma, LTD.The Complaint in Civil Action No. 5:20-cv-23 and all remaining claims, counterclaims, or affirmative defenses as to Aurobindo, are DISMISSED WITHOUT PREJUDICE and without costs, disbursements, or attorney fees to any party. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and any related agreement(s). Signed by Senior Judge Irene M. Keeley on 7/2/2021. (kac) (Entered: 07/02/2021) (4) |
| Jul 2, 2021 | 154 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced 7-2-2021 (Companion, James) (Entered: 07/02/2021) (2) |
| Jul 2, 2021 | 155 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Santanu Chakraborty (Companion, James) (Entered: 07/02/2021) (2) |
| Jul 2, 2021 | 156 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Beth Britton (Companion, James) (Entered: 07/02/2021) (2) |
| May 10, 2021 | 150 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced to Defendant Aurobindo 5/10/2021 (Companion, James) (Entered: 05/10/2021) (2) |
| May 10, 2021 | 151 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced to Defendant Mylan 5/10/2021 (Companion, James) (Entered: 05/10/2021) (2) |
| Apr 28, 2021 | 149 | Corporate Disclosure Statement by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. identifying Corporate Parent Mylan Inc. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent Viatris Inc. for Mylan Inc... (O'Brien, William) (Entered: 04/28/2021) (3) |
| Apr 23, 2021 | 148 | ORDER granting 147 Motion Stipulated Joint Motion to Extend Deadlines. Signed by Senior Judge Irene M. Keeley on 4/23/21. (jss) (Entered: 04/23/2021) (2) |
| Apr 21, 2021 | 147 | Joint MOTION To Extend Deadlines re 137 Order on Motion for Miscellaneous Relief,, Scheduling Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/21/2021) (Main Document) (4) |
| Apr 21, 2021 | 147 | Joint MOTION To Extend Deadlines re 137 Order on Motion for Miscellaneous Relief,, Scheduling Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/21/2021) (Proposed Order) (2) |
| Apr 20, 2021 | 146 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Responses and Objections to Defendants' Notice of Deposition Under Federal Rule of Civil Procedure 30(b)(6) (Companion, James) (Entered: 04/20/2021) (2) |
| Apr 15, 2021 | 144 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' documents served on Aurobindo 4-15-2021 (Companion, James) (Entered: 04/15/2021) (2) |
| Apr 15, 2021 | 145 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' documents served on Mylan defendants 4-15-2021 (Companion, James) (Entered: 04/15/2021) (2) |
| Apr 14, 2021 | 143 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 4.13.21). (O'Brien, William) (Entered: 04/14/2021) (2) |
| Apr 12, 2021 | 140 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Shane Shupe (Companion, James) (Entered: 04/12/2021) (2) |
| Apr 12, 2021 | 141 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Katie Reed (Companion, James) (Entered: 04/12/2021) (2) |
| Apr 12, 2021 | 142 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Santanu Chakraborty (Companion, James) (Entered: 04/12/2021) (2) |
| Mar 4, 2021 | 138 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents served on Aurobindo defendants on March 2, 2021 (Companion, James) (Entered: 03/04/2021) (2) |
| Mar 4, 2021 | 139 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents served on Mylan defendants on March 2, 2021 (Companion, James) (Entered: 03/04/2021) (2) |
| Mar 1, 2021 | 137 | ORDER: Order granting 135 Joint Motion to Extend Deadlines. Discovery due by 4/23/2021. Dispositive Motions due by 8/27/2021. Signed by Senior Judge Irene M. Keeley on 3/1/21. (jss) (Entered: 03/01/2021) (2) |
| Feb 26, 2021 | 131 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Objections and Responses to Mylan's First Joint Set of Rule 36 Requests for Admission (Nos. 1-40) and Plaintiffs' Response to Mylan's First Joint Set of Interrogatories to Plaintiffs (Nos. 1-20) (Companion, James) (Entered: 02/26/2021) (2) |
| Feb 26, 2021 | 132 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Response to Aurobindo's First Set of Rule 36 Requests for Admission (Nos. 1-40) and Plaintiffs' Response to Aurobindo's First Set of Interrogatories to Plaintiffs (Nos. 1-15) (Companion, James) (Entered: 02/26/2021) (2) |
| Feb 26, 2021 | 133 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 2.25.21). (O'Brien, William) (Entered: 02/26/2021) (2) |
| Feb 26, 2021 | 134 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Aurobindo's Responses and Objections to Plaintiffs' Requests for Admission. (Pizzo, John) (Entered: 02/26/2021) (1) |
| Feb 26, 2021 | 135 | Joint MOTION to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/26/2021) (Main Document) (4) |
| Feb 26, 2021 | 136 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-40)). (O'Brien, William) (Entered: 02/26/2021) (2) |
| Feb 26, 2021 | 135 | Joint MOTION to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/26/2021) (Proposed Order) (2) |
| Feb 19, 2021 | 130 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Responses and Objections to Plaintiffs Rule 30(B)(6) Notice of Deposition of Aurobindo Pharma Ltd. (Pizzo, John) (Entered: 02/19/2021) (1) |
| Feb 16, 2021 | 129 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Documents produced on 2.16.21). (O'Brien, William) (Entered: 02/16/2021) (2) |
| Feb 11, 2021 | 128 | Pro Hac Vice Filing fee for Tasha Francis Gerasimow: $ 200.00, receipt number WVNC003114 (jss) (Entered: 02/11/2021) (0) |
| Feb 10, 2021 | 125 | MOTION for Leave to Appear Pro Hac Vice of Tasha Gerasimow by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2021) (Main Document) (2) |
| Feb 10, 2021 | 126 | ORDER granting 125 Motion for Leave to Appear Pro Hac Vice re: Tasha Francis Gerasimow. Signed by Senior Judge Irene M. Keeley on 2/10/21. (njz) (Entered: 02/10/2021) (1) |
| Feb 10, 2021 | 127 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Markman Hearing held on 2/10/2021. (Court Reporter Cindy Knecht) (dk) (Entered: 02/10/2021) (0) |
| Feb 10, 2021 | 125 | MOTION for Leave to Appear Pro Hac Vice of Tasha Gerasimow by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/10/2021) (Proposed Order) (1) |
| Feb 3, 2021 | 118 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Hakaru Fujita. (Copland, Gordon) (Entered: 02/03/2021) (2) |
| Feb 3, 2021 | 119 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Kenjii Egusa. (Copland, Gordon) (Entered: 02/03/2021) (2) |
| Feb 3, 2021 | 120 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Megumi Maruyama. (Copland, Gordon) (Entered: 02/03/2021) (2) |
| Feb 3, 2021 | 121 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Taakiaki Nishioka. (Copland, Gordon) (Entered: 02/03/2021) (2) |
| Feb 3, 2021 | 122 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Thomas Friedl. (Copland, Gordon) (Entered: 02/03/2021) (2) |
| Feb 3, 2021 | 123 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Notice of Dep. of Michael Braun. (Copland, Gordon) (Entered: 02/03/2021) (2) |
| Feb 3, 2021 | 124 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of 30(b)(6) Deposition. (Pizzo, John) (Entered: 02/03/2021) (1) |
| Feb 2, 2021 | 114 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Klaus Dugi. (Pizzo, John) (Entered: 02/02/2021) (1) |
| Feb 2, 2021 | 115 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Eva Ulrike Graefe-Mody. (Pizzo, John) (Entered: 02/02/2021) (1) |
| Feb 2, 2021 | 116 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Ruth Harper. (Pizzo, John) (Entered: 02/02/2021) (1) |
| Feb 2, 2021 | 117 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. of Defendants' Notice of Deposition of Hans-Juergen Woerle. (Pizzo, John) (Entered: 02/02/2021) (1) |
| Feb 1, 2021 | 109 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Robert Cunard (Companion, James) (Entered: 02/01/2021) (2) |
| Feb 1, 2021 | 110 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Roopak Sawhney (Companion, James) (Entered: 02/01/2021) (2) |
| Feb 1, 2021 | 111 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of V. Naga Prasad (Companion, James) (Entered: 02/01/2021) (2) |
| Feb 1, 2021 | 112 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Akhilesh Dixit (Companion, James) (Entered: 02/01/2021) (2) |
| Feb 1, 2021 | 113 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Naresh Nagubandi (Companion, James) (Entered: 02/01/2021) (2) |
| Jan 28, 2021 | 108 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' First Set of Requests for Admission to Aurobindo (Companion, James) (Entered: 01/28/2021) (2) |
| Jan 27, 2021 | 105 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (First Joint Set of Rule 36 Requests for Admission (Nos. 1-40)). (O'Brien, William) (Entered: 01/27/2021) (2) |
| Jan 27, 2021 | 106 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (First Joint Set of Interrogatories to Plaintiffs (Nos. 1-20)). (O'Brien, William) (Entered: 01/27/2021) (2) |
| Jan 27, 2021 | 107 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. re 104 Certificate of Service (Amended). (Pizzo, John) (Entered: 01/27/2021) (1) |
| Jan 26, 2021 | 99 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Defendant Aurobindo Pharma Ltd. (Companion, James) (Entered: 01/26/2021) (2) |
| Jan 26, 2021 | 100 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Ashis Kumar Mehta (Companion, James) (Entered: 01/26/2021) (2) |
| Jan 26, 2021 | 101 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Shane Shupe (Companion, James) (Entered: 01/26/2021) (1) |
| Jan 26, 2021 | 102 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Notice of Deposition of Mylan defendants (Companion, James) (Entered: 01/26/2021) (2) |
| Jan 26, 2021 | 103 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. First Set of Rule 36 Requests for Admission (Nos. 1-40) to Plaintiffs. (Pizzo, John) (Entered: 01/26/2021) (1) |
| Jan 26, 2021 | 104 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. First Set of Interrogatories (Nos. 1-25) to Plaintiffs. (Pizzo, John) (Entered: 01/26/2021) (1) |
| Jan 22, 2021 | 98 | ORDER SCHEDULING CLAIM CONSTRUCTION HEARING: The Court SCHEDULES the claim construction hearing in these consolidated matters for February 10, 2021, at 10:00 a.m. by videoconference. Signed by Senior Judge Irene M. Keeley on 1/22/21. (jss) (Entered: 01/22/2021) (1) |
| Jan 21, 2021 | 93 | Pro Hac Vice Filing fee for Guylaine Hache: $ 200.00, receipt number WVNC003104 (jss) (Entered: 01/21/2021) (0) |
| Jan 21, 2021 | 94 | ORDER : Order granting 88 Pro Hac Vice Application of Guylaine Hache. Signed by Senior Judge Irene M. Keeley on 1/21/20. (jss) (Entered: 01/21/2021) (1) |
| Jan 21, 2021 | 95 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Response to Defendants' First Set of Common Requests for Documents and Things to Plaintiffs (Nos. 1-69) (Companion, James) (Entered: 01/21/2021) (2) |
| Jan 21, 2021 | 96 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced on Mylan Defendants on 1/20/2021 (Companion, James) (Entered: 01/21/2021) (2) |
| Jan 21, 2021 | 97 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re documents produced on Aurobindo on 1/20/2021 (Companion, James) (Entered: 01/21/2021) (2) |
| Jan 20, 2021 | 92 | DISCOVERY CONFIDENTIALITY ORDER. Signed by Senior Judge Irene M. Keeley on 1/20/21. (jss) (Entered: 01/20/2021) (30) |
| Jan 19, 2021 | 90 | Proposed Discovery Confidentiality Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 01/19/2021) (30) |
| Jan 19, 2021 | 91 | ORDER GRANTING JOINT MOTION TO RESCHEDULE CLAIM CONSTRUCTION HEARING [DKT. NO. 89 and continues the claim construction hearing to a date to be determined. Signed by Senior Judge Irene M. Keeley on 1/19/21. (jss) (Entered: 01/19/2021) (1) |
| Jan 18, 2021 | 89 | Joint MOTION To Reschedule Claim Construction Hearing by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/18/2021) (Main Document) (3) |
| Jan 18, 2021 | 89 | Joint MOTION To Reschedule Claim Construction Hearing by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/18/2021) (Proposed Order) (1) |
| Jan 15, 2021 | 88 | MOTION for Leave to Appear Pro Hac Vice (Guylaine Hache) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 01/15/2021) (Main Document) (3) |
| Jan 15, 2021 | 88 | MOTION for Leave to Appear Pro Hac Vice (Guylaine Hache) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 01/15/2021) (Proposed Order) (1) |
| Jan 12, 2021 | 87 | ORDER granting 86 Motion for Extension of Time and the completion of document production is extended toand including Tuesday, January 19, 2021. Signed by Senior Judge Irene M. Keeley on 1/12/21. (jss) (Entered: 01/12/2021) (1) |
| Jan 11, 2021 | 86 | MOTION for Extension of Time to File Joint Motion to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/11/2021) (Main Document) (3) |
| Jan 11, 2021 | 86 | MOTION for Extension of Time to File Joint Motion to Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 01/11/2021) (Proposed Order) (1) |
| Jan 8, 2021 | 82 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Objections and Responses to Plaintiff's First Set of Interrogatories (Pizzo, John) (Entered: 01/08/2021) (1) |
| Jan 8, 2021 | 83 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Objections and Responses to Plaintiffs' First Set of Requests for Production of Documents and Things (Pizzo, John) (Entered: 01/08/2021) (1) |
| Jan 8, 2021 | 84 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-10)). (O'Brien, William) (Entered: 01/08/2021) (2) |
| Jan 8, 2021 | 85 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Objections and Responses to Plaintiffs' First Set of Requests to Mylan for the Production of Documents and Things (Nos. 1-78)). (O'Brien, William) (Entered: 01/08/2021) (2) |
| Dec 21, 2020 | 81 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Defendants' First Set of Common Requests for Documents and Things to Plaintiffs (Nos. 1-69)). (O'Brien, William) (Entered: 12/21/2020) (2) |
| Dec 16, 2020 | 79 | Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Main Document) (16) |
| Dec 16, 2020 | 80 | Other Document PLAINTIFFS RESPONSIVE BRIEF ON CLAIM CONSTRUCTION filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 12/16/2020) (13) |
| Dec 16, 2020 | 79 | Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive) (2) |
| Dec 16, 2020 | 79 | Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 1 to Declaration) (30) |
| Dec 16, 2020 | 79 | Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 2 to Declaration) (11) |
| Dec 16, 2020 | 79 | Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 3 to Declaration) (11) |
| Dec 16, 2020 | 79 | Defendants' Responsive Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Affidavit Declaration of Wendy M. Ward in Support of Defendants' Responsive Claim Construction Brief, # 2 Exhibit Exhibit 1 to Declaration, # 3 Exhibit Exhibit 2 to Declaration, # 4 Exhibit Exhibit 3 to Declaration, # 5 Exhibit Exhibit 4 to Declaration)(Pizzo, John) (Entered: 12/16/2020) (Exhibit Exhibit 4 to Declaration) (11) |
| Dec 11, 2020 | 78 | ORDER: ORDERED that the deadline for the completion of document production is extended to and including Monday, January 11, 2021. Signed by Senior Judge Irene M. Keeley on 12/11/20. (jss) (Entered: 12/11/2020) (1) |
| Dec 10, 2020 | 77 | Joint MOTION To Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 12/10/2020) (Main Document) (3) |
| Dec 10, 2020 | 77 | Joint MOTION To Extend Deadline by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 12/10/2020) (Proposed Order) (1) |
| Nov 25, 2020 | 75 | Joint MOTION for Extension of Time to Complete Discovery to extend deadline for substantial completion of document production by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order Text of Proposed Order)(Law, Sandra) (Entered: 11/25/2020) (Main Document) (3) |
| Nov 25, 2020 | 76 | ORDER: ORDERED that the deadline for the completion of document production is extended to and including Friday, December 11, 2020. Signed by Senior Judge Irene M. Keeley on 11/25/20. (jss) (Entered: 11/25/2020) (1) |
| Nov 25, 2020 | 75 | Joint MOTION for Extension of Time to Complete Discovery to extend deadline for substantial completion of document production by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order Text of Proposed Order)(Law, Sandra) (Entered: 11/25/2020) (Proposed Order Text of Proposed Order) (1) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Main Document) (23) |
| Nov 16, 2020 | 73 | Defendants' Opening Claim Construction Brief Other Document filed by Aurobindo Pharma, LTD.. (Pizzo, John) (Entered: 11/16/2020) (11) |
| Nov 16, 2020 | 74 | Joint Defendants' Opening Claim [Corrected]Construction Brief Other Document filed by Aurobindo Pharma, LTD.. (Pizzo, John) (Entered: 11/16/2020) (12) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Attachment Declaration of Attorney James F. Companion) (3) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 1) (30) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 2) (5) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 3) (8) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 4) (14) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 5) (30) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 6) (30) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 7) (22) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 8) (30) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 9) (30) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 10) (6) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 11) (14) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 12) (14) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 13) (5) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 14) (30) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 15) (21) |
| Nov 16, 2020 | 72 | Plaintiffs' Opening Claim Construction Brief Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment Declaration of Attorney James F. Companion, # 2 Exhibit 1, # 3 Exhibit 2, # 4 Exhibit 3, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11, # 13 Exhibit 12, # 14 Exhibit 13, # 15 Exhibit 14, # 16 Exhibit 15, # 17 Exhibit 16)(Companion, James) (Entered: 11/16/2020) (Exhibit 16) (4) |
| Oct 21, 2020 | 71 | Joint Claim Construction and Pre-Hearing Statement Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Companion, James) (Entered: 10/21/2020) (Main Document) (4) |
| Oct 21, 2020 | 71 | Joint Claim Construction and Pre-Hearing Statement Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Companion, James) (Entered: 10/21/2020) (Exhibit A) (6) |
| Oct 15, 2020 | 70 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Disputed Terms and Proposed Constructions and Initial Identification of Intrinsic Evidence (Companion, James) (Entered: 10/15/2020) (2) |
| Oct 14, 2020 | 69 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Defendants' Proposed Claim Constructions and Preliminary Identification of Intrinsic Evidence. (Pizzo, John) (Entered: 10/14/2020) (1) |
| Oct 7, 2020 | 67 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. Defendants' Identification of Proposed Terms for Claim Construction. (Pizzo, John) (Entered: 10/07/2020) (2) |
| Oct 7, 2020 | 68 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. for Plaintiffs' Identification of Terms for Construction. (Companion, James) (Entered: 10/07/2020) (2) |
| Oct 1, 2020 | 66 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. PLAINTIFFS RESPONSE TO DEFENDANTS INVALIDITY CONTENTIONS. (Companion, James) (Entered: 10/01/2020) (2) |
| Sep 30, 2020 | 64 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Defendant Aurobindo Pharma Ltd.s Preliminary Noninfringement Contentions for U.S. Patent No. 9,486,526. (Pizzo, John) (Entered: 09/30/2020) (1) |
| Sep 30, 2020 | 65 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Preliminary Responses to Plaintiffs' Infringement Contentions). (O'Brien, William) (Entered: 09/30/2020) (2) |
| Aug 4, 2020 | 63 | PLAINTIFFS' ANSWER to 48 Answer to Complaint,, Counterclaim, of Defendants by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc..(Companion, James) (Entered: 08/04/2020) (14) |
| Aug 3, 2020 | 60 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD., Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Defendants' Initial Invalidity Contentions). (O'Brien, William) (Entered: 08/03/2020) (2) |
| Aug 3, 2020 | 61 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. Plaintiffs' Contentions Against Mylan. (Companion, James) (Entered: 08/03/2020) (2) |
| Aug 3, 2020 | 62 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. Plaintiffs' Contentions Against Aurobindo. (Companion, James) (Entered: 08/03/2020) (2) |
| Jul 17, 2020 | 58 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs' Rule 26(a) Supplemental Initial Disclosure Statement (Companion, James) (Entered: 07/17/2020) (2) |
| Jul 17, 2020 | 59 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Initial Disclosures Pursuant to Rule 26(a)(1)). (O'Brien, William) (Entered: 07/17/2020) (2) |
| Jul 14, 2020 | 57 | Defendants' Answer to Plaintiffs' Complaint and Counterclaims in consolidated CAN 1:20CV90 ( Other Document ) filed by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 07/14/2020) (28) |
| Jul 10, 2020 | 56 | CERTIFICATE OF SERVICE by Aurobindo Pharma, LTD. Aurobindo Defendants Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1). (Pizzo, John) (Entered: 07/10/2020) (2) |
| Jul 8, 2020 | 55 | CONSENT ORDER OF CONSOLIDATION FOR ALL PURPOSESAND SCHEDULING ORDER: Initial Disclosures due by 7/17/2020. Dispositive Motions due by 8/10/2020. Claim Construction set for 1/20/2021 at 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Telephonic Status Conference set for 7/20/2021 at 01:00 PM before Senior Judge Irene M. Keeley. Proposed Pretrial Order due by 12/17/2021. Final Pretrial Conference set for 1/14/2022 at 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Bench Trial set for 1/24/2022 at 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. (5 days) Signed by Senior Judge Irene M. Keeley on 7/8/20. (jss) (Entered: 07/08/2020) (5) |
| Jul 7, 2020 | 54 | Proposed Consent Order of Consolidation for All Purposes and Scheduling Order by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 07/07/2020) (5) |
| Jun 17, 2020 | 53 | Plaintiffs' Answer to Defendant Aurobindo's Counterclaims Other Document filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Companion, James) (Entered: 06/17/2020) (7) |
| Jun 16, 2020 | 52 | ORDER ADOPTING SCHEDULING ORDER. Signed by Senior Judge Irene M. Keeley on 6/16/20. (jss) (Entered: 06/16/2020) (1) |
| Jun 15, 2020 | 51 | ORDER GRANTING MOTION TO CONSOLIDATE (filed in Civil Action No. 5:20-cv-23). Signed by District Judge John Preston Bailey on 6/15/2020. (copy to counsel via cm/ecf) (nmm) (Entered: 06/15/2020) (3) |
| Jun 2, 2020 | 50 | ANSWER to 48 Answer to Complaint,, Counterclaim, by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc..(Companion, James) (Entered: 06/02/2020) (11) |
| May 13, 2020 | 49 | Corporate Disclosure Statement by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. identifying Corporate Parent Mylan Inc., Corporate Parent Mylan N.V. for Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.; Corporate Parent Mylan N.V. for Mylan Inc... (O'Brien, William) (Entered: 05/13/2020) (3) |
| May 12, 2020 | 48 | Mylan Defendants' ANSWER to 1 Complaint, and affirmative defenses and, COUNTERCLAIM for declaratory and other relief against Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. by Mylan Inc., Mylan Pharmaceuticals Inc., Mylan Laboratories Limited.(Copland, Gordon) (Entered: 05/12/2020) (22) |
| May 8, 2020 | 47 | Document filed in wrong case. Document was filed in proper case 1:20cv90 and NEF regenerated (Main Document 47 replaced on 5/11/2020) (jss). Modified on 5/11/2020 (jss). (Entered: 05/08/2020) (1) |
| May 4, 2020 | 45 | CERTIFICATE OF SERVICE by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. re Plaintiffs Rule 26(a) Initial Disclosure Statement (Companion, James) (Entered: 05/04/2020) (1) |
| May 4, 2020 | 46 | CERTIFICATE OF SERVICE by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (Defendants' Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1)). (O'Brien, William) (Entered: 05/04/2020) (2) |
| May 1, 2020 | 44 | SCHEDULING ORDER: Claim construction hearing set for 1/20/2021 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Discovery due by 2/26/2021. Status Conference set for 7/20/2021 01:00 PM in Judge Keeley Chambers before Senior Judge Irene M. Keeley. Dispositive motions due by 8/10/2021. Proposed Pretrial Order due by 12/17/2021. Pretrial Conference/Final Settlement Conference set for 1/14/2022 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Bench Trial set for 1/24/2022 09:30 AM in Clarksburg District Judge Courtroom, 2nd Floor before Senior Judge Irene M. Keeley. Signed by Senior Judge Irene M. Keeley on 5/1/2020. (cnd) (Entered: 05/01/2020) (14) |
| Apr 27, 2020 | 43 | MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Senior Judge Irene M. Keeley. Scheduling Conference held on 4/27/2020. (Court Reporter Stacy Harlow) (dk) (Entered: 04/27/2020) (0) |
| Apr 23, 2020 | 40 | Pro Hac Vice Filing fees for B. Hales and J. Hurst: $ 400.00, receipt number WVNC002907 (jss) (Entered: 04/23/2020) (0) |
| Apr 23, 2020 | 41 | ORDER granting Bryan S. Hales' 38 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 4/23/20. (jss) (Entered: 04/23/2020) (1) |
| Apr 23, 2020 | 42 | ORDER granting James F. Hurst's 36 37 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 4/23/20. (jss) (Entered: 04/23/2020) (1) |
| Apr 21, 2020 | 39 | REPORT of Rule 26(f) Planning Meeting. (Copland, Gordon) (Entered: 04/21/2020) (14) |
| Apr 20, 2020 | 37 | MOTION to Amend/Correct 36 MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Main Document) (3) |
| Apr 20, 2020 | 38 | MOTION for Leave to Appear Pro Hac Vice of Bryan S. Hales by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Main Document) (3) |
| Apr 20, 2020 | 37 | MOTION to Amend/Correct 36 MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Proposed Order) (1) |
| Apr 20, 2020 | 38 | MOTION for Leave to Appear Pro Hac Vice of Bryan S. Hales by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Attachment) (1) |
| Apr 20, 2020 | 38 | MOTION for Leave to Appear Pro Hac Vice of Bryan S. Hales by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Attachment, # 2 Proposed Order)(Companion, James) (Entered: 04/20/2020) (Proposed Order) (1) |
| Apr 16, 2020 | 36 | MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/16/2020) (Main Document) (3) |
| Apr 16, 2020 | 36 | MOTION for Leave to Appear Pro Hac Vice of James F. Hurst by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/16/2020) (Proposed Order) (1) |
| Apr 10, 2020 | 34 | Joint MOTION for Extension of Time to File Rule 26(f) Report by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/10/2020) (Main Document) (3) |
| Apr 10, 2020 | 35 | ORDER: Order granting 34 Motion for Extension of Time to File and the Rule 26(f) planning reports are due on or before 4/20/20. Signed by Senior Judge Irene M. Keeley on 4/10/20. (jss) (Entered: 04/10/2020) (1) |
| Apr 10, 2020 | 34 | Joint MOTION for Extension of Time to File Rule 26(f) Report by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 04/10/2020) (Proposed Order) (1) |
| Apr 9, 2020 | 33 | STIPULATION REGARDING RESPONSIVE PLEADING DEADLINE (MAY12, 2020) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 04/09/2020) (3) |
| Apr 2, 2020 | 31 | MOTION to Withdraw of Atty. Leora Ben-Ami as counsel for Plaintiffs by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/02/2020) (Main Document) (2) |
| Apr 2, 2020 | 32 | ORDER granting 31 Motion to Withdraw of Atty. Leora Ben-Ami as counsel for Plaintiffs. Signed by Senior Judge Irene M. Keeley on 4/2/20. (jss) (Entered: 04/02/2020) (1) |
| Apr 2, 2020 | 31 | MOTION to Withdraw of Atty. Leora Ben-Ami as counsel for Plaintiffs by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 04/02/2020) (Proposed Order) (1) |
| Mar 4, 2020 | 27 | ORDER granting Joseph M. Janusz's 26 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 3/4/20. (jss) (Entered: 03/04/2020) (1) |
| Mar 4, 2020 | 28 | ORDER granting Deepro R. Mukerjee's 25 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 3/4/20. (jss) (Entered: 03/04/2020) (1) |
| Mar 4, 2020 | 29 | ORDER granting Lance A. Soderstrom's 24 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 3/4/20. (jss) (Entered: 03/04/2020) (1) |
| Mar 4, 2020 | 30 | Pro Hac Vice Filing fees for D. Mukerjee, L. Soderstrom and J. Janusz: $ 600.00, receipt number WVNC002874 (jss) (Entered: 03/04/2020) (0) |
| Mar 3, 2020 | 24 | MOTION for Leave to Appear Pro Hac Vice (Lance A. Soderstrom) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Main Document) (3) |
| Mar 3, 2020 | 25 | MOTION for Leave to Appear Pro Hac Vice (Deepro R. Mukerjee) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Main Document) (3) |
| Mar 3, 2020 | 26 | MOTION for Leave to Appear Pro Hac Vice (Joseph M. Janusz) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Main Document) (3) |
| Mar 3, 2020 | 25 | MOTION for Leave to Appear Pro Hac Vice (Deepro R. Mukerjee) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Proposed Order) (1) |
| Mar 3, 2020 | 26 | MOTION for Leave to Appear Pro Hac Vice (Joseph M. Janusz) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Proposed Order) (1) |
| Mar 3, 2020 | 24 | MOTION for Leave to Appear Pro Hac Vice (Lance A. Soderstrom) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(O'Brien, William) (Entered: 03/03/2020) (Proposed Order) (1) |
| Feb 28, 2020 | 22 | WAIVER OF SERVICE Returned Executed by Mylan Laboratories Limited. Mylan Laboratories Limited waiver sent on 2/12/2020, answer due 4/13/2020. (O'Brien, William) (Entered: 02/28/2020) (1) |
| Feb 28, 2020 | 23 | STIPULATION REGARDING RESPONSIVE PLEADING DEADLINE (APRIL 12, 2020) by Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc.. (O'Brien, William) (Entered: 02/28/2020) (3) |
| Feb 14, 2020 | 20 | SUMMONS Returned Executed as to Mylan Pharmaceuticals Inc. service accepted by SOS on 2/6/2020. (jss) (Entered: 02/14/2020) (4) |
| Feb 14, 2020 | 21 | SUMMONS Returned Executed as to Mylan Inc. service accepted by SOS on 2/6/2020. (jss) (Entered: 02/14/2020) (4) |
| Feb 13, 2020 | 11 | MOTION for Leave to Appear Pro Hac Vice of Leora Ben-Ami by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (3) |
| Feb 13, 2020 | 12 | MOTION for Leave to Appear Pro Hac Vice of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (3) |
| Feb 13, 2020 | 13 | MOTION for Leave to Appear Pro Hac Vice of Jeanna Wacker by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (3) |
| Feb 13, 2020 | 14 | MOTION to Withdraw as Counsel of Attorneys Thomas F. Fleming, Sam Kwon, Ashley Ross and Christopher J. Citro by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Main Document) (2) |
| Feb 13, 2020 | 15 | Pro Hac Vice fees for Leora Ben-Ami, Mira Mulvaney, and Jeanna Wacker: $ 600.00, receipt number WVNC002861. (cnd) (Entered: 02/13/2020) (0) |
| Feb 13, 2020 | 16 | ORDER: It is ORDERED that the Court GRANTS Plaintiffs' 14 Motion for Leave to Withdraw as Counsel. Attorneys Sam Kwon, Ashley Ross, Christopher J. Citro and Thomas F. Fleming terminated. Signed by Senior Judge Irene M. Keeley on 2/13/2020. (cnd) (Entered: 02/13/2020) (1) |
| Feb 13, 2020 | 17 | ORDER granting Leona Ben-Ami's 11 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 2/13/20. (jss) (Entered: 02/13/2020) (1) |
| Feb 13, 2020 | 18 | ORDER granting Mira Mulvaney's 12 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 2/13/20. (jss) (Entered: 02/13/2020) (1) |
| Feb 13, 2020 | 19 | ORDER granting Jeanna Wacker's 13 Motion for Leave to Appear pro hac vice. Signed by Senior Judge Irene M. Keeley on 2/13/20. (jss) (Entered: 02/13/2020) (1) |
| Feb 13, 2020 | 12 | MOTION for Leave to Appear Pro Hac Vice of Mira Mulvaney by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1) |
| Feb 13, 2020 | 13 | MOTION for Leave to Appear Pro Hac Vice of Jeanna Wacker by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1) |
| Feb 13, 2020 | 11 | MOTION for Leave to Appear Pro Hac Vice of Leora Ben-Ami by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1) |
| Feb 13, 2020 | 14 | MOTION to Withdraw as Counsel of Attorneys Thomas F. Fleming, Sam Kwon, Ashley Ross and Christopher J. Citro by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc.. (Attachments: # 1 Proposed Order)(Companion, James) (Entered: 02/13/2020) (Proposed Order) (1) |
| Feb 12, 2020 | 10 | ORDER -- FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 3/30/2020. Rule 26 Meeting Report due by 4/13/2020. Scheduling Conference set for 4/27/2020 at 01:00 PM in Judge Keeley Chambers before Senior Judge Irene M. Keeley. Discovery due by 5/4/2020. Signed by Senior Judge Irene M. Keeley on 2/12/20. (jss) (Entered: 02/12/2020) (3) |
| Feb 11, 2020 | 9 | NOTICE of Appearance by William J O'Brien on behalf of Mylan Inc., Mylan Laboratories Limited, Mylan Pharmaceuticals Inc. (O'Brien, William) (Entered: 02/11/2020) (2) |
| Feb 5, 2020 | 1 | Complaint* (1) |
| Feb 5, 2020 | 2 | Supplemental Information for Patent Cases Involving an Abbreviated New Drug Application (ANDA) filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals Inc. (jss) (Entered: 02/05/2020) (2) |
| Feb 5, 2020 | 3 | Corporate Disclosure Statement. (jss) (Entered: 02/05/2020) (2) |
| Feb 5, 2020 | 4 | REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (jss) (Entered: 02/05/2020) (1) |
| Feb 5, 2020 | 5 | Filing fee: $ 400.00, receipt number WVNW002384 (jss) (Entered: 02/05/2020) (0) |
| Feb 5, 2020 | 8 | VERIFICATION OF ATTORNEY ADMISSION as to L. Ben-Ami, T. Fleming, J. Wacker, M. Mulvaney, S. Kwon, A. Ross and C. Citro. (jss) (Entered: 02/05/2020) (1) |
